Nissay Asset Management Corp Biogen Inc. Transaction History

Nissay Asset Management Corp

$16.7 Billion
Q2 2025

A detailed history of Nissay Asset Management Corp transactions in Biogen Inc. stock. As of the latest transaction made, Nissay Asset Management Corp holds 44,818 shares of BIIB stock, worth $6.71 Million. This represents 0.03% of its overall portfolio holdings.

Number of Shares

44,818

Previous 47,204 5.05%

Holding current value

$6.71 Million

Previous $6.46 Million 12.87%

% of portfolio

0.03%

Previous 0.04%

31 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 14, 2025	SELL	$113.38 - $135.49 $270,524 - $323,279	-2,386 Reduced 5.05%	44,818 $5.63 Million
Q1 2025 May 15, 2025	BUY	$133.43 - $153.27 $443,654 - $509,622	3,325 Added 7.58%	47,204 $6.46 Million
Q4 2024 Feb 14, 2025	BUY	$146.47 - $191.55 $201,982 - $264,147	1,379 Added 3.24%	43,879 $6.71 Million
Q3 2024 Nov 14, 2024	BUY	$189.07 - $236.8 $490,069 - $613,785	2,592 Added 6.49%	42,500 $8.24 Million
Q2 2024 Aug 14, 2024	BUY	$190.52 - $236.72 $1.44 Million - $1.79 Million	7,563 Added 23.38%	39,908 $9.25 Million
Q1 2024 May 15, 2024	BUY	$212.02 - $267.71 $2.74 Million - $3.45 Million	12,901 Added 66.35%	32,345 $6.97 Million
Q4 2023 Feb 14, 2024	BUY	$222.59 - $267.94 $392,426 - $472,378	1,763 Added 9.97%	19,444 $5.03 Million
Q3 2023 Nov 14, 2023	BUY	$253.3 - $285.89 $334,102 - $377,088	1,319 Added 8.06%	17,681 $4.54 Million
Q2 2023 Aug 14, 2023	SELL	$275.25 - $318.06 $14,037 - $16,221	-51 Reduced 0.31%	16,362 $4.66 Million
Q1 2023 May 15, 2023	SELL	$256.56 - $292.34 $158,297 - $180,373	-617 Reduced 3.62%	16,413 $4.56 Million
Q4 2022 Feb 14, 2023	SELL	$252.44 - $306.72 $50,992 - $61,957	-202 Reduced 1.17%	17,030 $4.72 Million
Q3 2022 Nov 14, 2022	BUY	$194.69 - $268.46 $110,194 - $151,948	566 Added 3.4%	17,232 $4.6 Million
Q2 2022 Aug 15, 2022	BUY	$187.54 - $223.02 $10,127 - $12,043	54 Added 0.33%	16,666 $3.4 Million
Q1 2022 May 16, 2022	BUY	$193.77 - $244.14 $31,390 - $39,550	162 Added 0.98%	16,612 $3.5 Million
Q4 2021 Feb 14, 2022	SELL	$223.92 - $287.77 $218,098 - $280,287	-974 Reduced 5.59%	16,450 $3.95 Million
Q3 2021 Nov 10, 2021	BUY	$282.99 - $369.05 $103,857 - $135,441	367 Added 2.15%	17,424 $4.93 Million
Q2 2021 Aug 13, 2021	SELL	$259.0 - $414.71 $391,090 - $626,212	-1,510 Reduced 8.13%	17,057 $5.91 Million
Q1 2021 May 11, 2021	SELL	$242.95 - $284.63 $181,969 - $213,187	-749 Reduced 3.88%	18,567 $5.19 Million
Q4 2020 Feb 08, 2021	SELL	$236.26 - $355.63 $223,738 - $336,781	-947 Reduced 4.67%	19,316 $4.73 Million
Q3 2020 Oct 20, 2020	SELL	$264.77 - $305.71 $1.13 Million - $1.3 Million	-4,268 Reduced 17.4%	20,263 $5.75 Million
Q2 2020 Jul 27, 2020	SELL	$258.66 - $342.55 $25,090 - $33,227	-97 Reduced 0.39%	24,531 $6.56 Million
Q1 2020 May 05, 2020	BUY	$268.85 - $341.04 $13,442 - $17,052	50 Added 0.2%	24,628 $7.79 Million
Q4 2019 Feb 14, 2020	SELL	$220.06 - $304.07 $341,313 - $471,612	-1,551 Reduced 5.94%	24,578 $7.29 Million
Q3 2019 Nov 14, 2019	BUY	$217.44 - $243.88 $150,685 - $169,008	693 Added 2.72%	26,129 $6.08 Million
Q2 2019 Aug 07, 2019	SELL	$219.29 - $241.72 $85,303 - $94,029	-389 Reduced 1.51%	25,436 $5.95 Million
Q1 2019 May 03, 2019	SELL	$216.71 - $338.96 $130,242 - $203,714	-601 Reduced 2.27%	25,825 $6.11 Million
Q4 2018 Feb 06, 2019	SELL	$278.5 - $352.75 $224,192 - $283,963	-805 Reduced 2.96%	26,426 $7.95 Million
Q3 2018 Oct 30, 2018	BUY	$293.51 - $383.83 $141,765 - $185,389	483 Added 1.81%	27,231 $9.62 Million
Q2 2018 Aug 08, 2018	BUY	$257.52 - $306.91 $397,353 - $473,562	1,543 Added 6.12%	26,748 $7.76 Million
Q1 2018 May 14, 2018	SELL	$260.13 - $367.91 $255,447 - $361,287	-982 Reduced 3.75%	25,205 $6.9 Million
Q4 2017 Feb 14, 2018	BUY	$307.64 - $344.58 $8.06 Million - $9.02 Million	26,187	26,187 $8.34 Million

Others Institutions Holding BIIB

# of Institutions

1,038

Shares Held

131M

Call Options Held

2.84M

Put Options Held

2.54M

View Full List

About BIOGEN INC.

Ticker BIIB
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 144,000,992
Market Cap $21.5B
Description
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...

More about BIIB

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Nissay Asset Management Corp , based on Form 13F filings with the SEC.

News

Stay updated on Nissay Asset Management Corp with notifications on news.

Account

Nissay Asset Management Corp Biogen Inc. Transaction History